Poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors: Mechanisms of Action, Structural Optimization, and Combination Therapeutic Strategies in Cancer Therapy
In recent years, poly(ADP-ribose) glycohydrolase (PARG), a key enzyme in DNA damage repair pathways, has emerged as a major focus in anticancer drug discovery. PARG inhibitors exhibit broad-spectrum antitumor effects across diverse tumor types via multiple mechanisms, such as triggering sustained nuclear replication stress and mitotic catastrophe, as well as modulating the stability of cell cycle checkpoint proteins. This review systematically summarizes the mechanisms of action of PARG inhibitors, recent advances in their structural optimization, and their applications in combination with immunotherapy, ATR/CHK1 inhibitors, and natural products, aiming to highlight the unique value and clinical translation prospects of PARG inhibitors as a new generation of highly selective, multi-mechanism antitumor agents.
Authors
- Guangzhi Shan (ORCID: https://orcid.org/0000-0003-0646-2874)
- Xiaodan Qiu (ORCID: https://orcid.org/0009-0009-2480-4728)
- Kun Xiao (ORCID: https://orcid.org/0000-0002-8039-3283)
- Biao Li (ORCID: https://orcid.org/0000-0002-7359-3690)
- Limin Zuo (ORCID: https://orcid.org/0009-0001-7118-8798)
- Zhiling Zhu (ORCID: https://orcid.org/0009-0004-0859-0129)
- Yiran Li
- Yechun Zhang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institute of Medicinal Plant Development (CN)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3390/pharmaceutics18111496
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine